Vaccine by China’ Sinovac Biotech appears safe in preliminary results

NEW DELHI: A coronavirus vaccine developed by Sinovac Biotech, a China based pharmaceutical company, has appeared to be safe in its last-stage clinical trial. Brazil’s Sao Paulo’s Butantan Institute has been carrying out the Phase III tests on the CoronaVac, which proved to be safe in preliminary results based on trials involving 9,000 volunteers.

Reuters, a news agency, reported that there were no severe or adverse reactions to the vaccine. 20 per cent of the volunteers reported mild pain from the injection while 15 per cent reported headaches after the first dose, which dropped to 10 per cent for the second. Less than 5 per cent volunteers reported nausea, tiredness or muscle-ache.